Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Erratum
DOI
PMC
 |
|
|
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
Correction: Longitudinal association between DNA methylation and type 2 diabetes: Findings from the KORA F4/FF4 study.
Cardiovasc. Diabetol. 24:252 (2025)
In the original publication of this article [1], the author noticed the following errors in author names, figure captions and Table 1. The original article has been updated. The author’s name “Monica Del C Gomez-Alonso” was incorrectly identified as two separate individuals “Monica Del and C Gomez-Alonso”. Fig. 1 Illustration of the selection criteria for study participants and CpG sites included in the analysis. Fig. 2 Miami plot illustrating EWAS results associated with T2D. The x axis indicates the chromosome location, and the y-axis represents the −log10 (p-value). The Bonferroni threshold of 1.34×10−7 is marked by a red dashed line, while the Benjamini–Hochberg (FDR) threshold (p_FDR < 0.05) is indicated by a blue solid line. The upper side represents the positive estimates, and the lower side represents the negative estimates. Fig. 3 Volcano plots illustrating the results for glycemic traits. The x axis indicates the effect size, and the y-axis represents the −log10 (p-value). The Bonferroni threshold of p=1.34×10−7 is marked by a red dashed line, while the Benjamini–Hochberg (FDR) threshold (p_FDR < 0.05) is indicated by a blue dashed line. (A) Volcano plot for FPG. (B) Volcano plot for HbA1c. (C) Volcano plot for HOMA-B. (D) Volcano plot for HOMA-IR. Fig. 4 Line plots illustrating the rate of methylation change over time for the NGT and T2D groups. The red and blue line represents the individuals with NGT and T2D, respectively. (A) cg19693031 (TXNIP); (B) cg00574958 (CPT1A); (C) cg15418499 (IL18); (D) cg20507228 (MAN2A2). Fig. 5 Venn diagram illustrating the overlap of CpG sites (with annotated gene names) in the sensitivity analysis. The light cyan colour represents the number of significant CpG sites associated with T2D in the main analysis with all individuals. The greyish-yellow colour represents the number of significant CpG sites associated with T2D in the extended models with all individuals. The light pink colour represents the number of significant CpG sites associated with T2D from individuals with repeated methylation measurements at two time points. Fig. 6 Volcano plots illustrating the association between DNA methylation and changing diabetes status over time. The x axis indicates the effect size, and the y-axis represents the −log10 (p-value). The Bonferroni threshold of 2.27×10−3 is marked by a red dashed line, while the Benjamini–Hochberg (FDR) threshold (p_FDR < 0.05) is indicated by a blue dashed line. (A) Volcano plot for the persistent prediabetes or T2D. (B) Volcano plot for the progression of diabetes. In Table 1, there are two cohorts, each consisting of four columns. The column titled "T2D N=245" from “KORA F4” cohort has been mistakenly indicated as belonging to “KORA FF4” cohort by a line marker. The correct version of Table 1 has displayed below. Characteristics of the study population Characteristics KORA F4 KORA FF4 All N = 1696 NGT N = 1113 Prediabetes N = 338 T2D N = 245 All N = 1805 NGT N = 1262 Prediabetes N = 304 T2D N = 239 Age (years) 61 (14) 58 (14) 65 (14) 67 (10) 58 (18) 54.5 (16) 63 (16) 68 (13.5) Male (%) 828 (48.8%) 499 (44.8%) 184 (54.4%) 145 (59.2%) 868 (48.1%) 554 (43.9%) 172 (56.6%) 142 (59.4%) BMI (kg/m2) 27.5 (5.8) 26.2(5.2) 29.3 (5.7) 30.7(6.7) 27.0 (6.2) 26.0 (5.4) 29.2 (5.2) 30.4 (7.2) Never smoker 710 (41.9%) 460 (41.3%) 156 (46.2%) 94 (38.4%) 746 (41.3%) 522 (41.4%) 118 (38.8%) 106 (44.4%) Former smoker 737 (43.5%) 462 (41.5%) 156 (46.2%) 119 (48.6%) 766 (42.4%) 517 (41.0%) 138 (45.4%) 111 (46.4%) Current smoker 247 (14.6%) 189 (17.0%) 26 (7.7%) 32 (13.1%) 293 (16.2%) 223 (17.7%) 48 (15.8%) 22 (9.2%) Hypertension (%) 772 (45.5%) 377 (33.9%) 198 (58.6%) 197 (80.4%) 646 (35.8%) 317 (25.1%) 159 (52.3%) 170 (71.1%) Fasting glucose 5.4 (0.9) 5.2 (0.6) 5.8 (0.9) 6.9 (1.9) 5.4 (0.9) 5.2 (0.6) 6.1 (0.8) 7.2 (2.0) HOMA-IR 2.2 (1.8) 1.9 (1.3) 3.1 (2.5) 5.1 (4.0) 2.1 (1.9) 1.8 (1.4) 3.5 (2.2) 4.8 (4.2) HOMA-beta 102.0 (65.7) 101.0 (62.7) 110.0 (79.0) 93.5 (97.4) 94.8 (65.5) 93.1 (61.0) 110.0 (87.7) 102. (70.3) HbA1c 37.0 (6.0) 36.0 (5.0) 38.5 (5.0) 46.0 (12.0) 36.0 (6.0) 34.0 (5.0) 38.0 (5.0) 45.0 (10.8) HDL-cholesterol 1.4 (0.5) 1.5 (0.5) 1.3 (0.5) 1.2 (0.4) 1.6 (0.7) 1.7 (0.7) 1.5 (0.6) 1.4 (0.5) Triglycerides 1.3 (0.9) 1.1 (0.8) 1.5 (1.0) 1.7 (1.2) 1.2 (0.8) 1.1 (0.7) 1.5 (1.0) 1.6 (1.2) Medication 128.0 (7.6%) 0 (0%) 0 (0%) 128 (52.2%) 133 (7.4%) 0 (0%) 0 (0%) 133 (55.6%) Yes 380 (22.4%) 239 (21.5%) 71 (21.0%) 70 (28.6%) 501 (27.8%) 314 (24.9%) 94 (30.9%) 93 (38.9%) No 773 (45.6%) 582 (52.3%) 135 (39.9%) 56 (22.9%) 1131 (62.7%) 844 (66.9%) 177 (58.2%) 110 (46.0%) Unknown 254 (15.0%) 159 (14.3%) 53 (15.7%) 42 (17.1%) 173 (9.6%) 104 (8.2%) 33 (10.9%) 36 (15.1%) Data are median (IQR) for continuous variables and n (%) for categorical variables. The unit for both fasting glucose and HbA1c is mmol/mol. The unit for both HDL-cholesterol and triglycerides is mmol/l. Medication means the glucose-lowering medication
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Sonstiges: Korrektur, Ergänzung
ISSN (print) / ISBN
1475-2840
e-ISSN
1475-2840
Zeitschrift
Cardiovascular Diabetology
Quellenangaben
Band: 24,
Heft: 1,
Artikelnummer: 252
Verlag
BioMed Central
Verlagsort
Campus, 4 Crinan St, London N1 9xw, England
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Epidemiology (EPI)
Institute of Neurogenomics (ING)
Institute of Neurogenomics (ING)